Alexa Hetzel, MS, PA-C

Andrew Mastro, MS, PA-C, asks Alexa Hetzel, MS, PA-C, whether efficacy and durability drive first-time systemic treatment decisions or whether route of administration and patient comfort carry more weight in practice.

Returning after a break in filming, Andrew Mastro, MS, PA-C, asks Alexa Hetzel, MS, PA-C, whether a persistent gap remains in plaque psoriasis care despite the expanding menu of oral and injectable options, whether tied to a specific patient population or to access itself.

Andrew Mastro, MS, PA-C, closes out this stretch of the conversation by asking Alexa Hetzel, MS, PA-C, to look three to five years ahead and describe how she expects the plaque psoriasis treatment paradigm to evolve.

Andrew Mastro, MS, PA-C, widens the lens and asks Alexa Hetzel, MS, PA-C, where icotrokinra sits within the broader plaque psoriasis landscape, including whether route of administration itself shapes patient preference.

Andrew Mastro, MS, PA-C, asks Alexa Hetzel, MS, PA-C, to describe the patient profile she has in mind when reaching for icotrokinra.

The discussion turns to mechanism of action as Andrew Mastro, MS, PA-C, asks Alexa Hetzel, MS, PA-C, where icotrokinra sits conceptually relative to the biologic classes that have anchored psoriasis treatment.

Andrew Mastro, MS, PA-C, turns the conversation to a population clinicians often approach with extra caution, adolescents with plaque psoriasis, asking Alexa Hetzel, MS, PA-C, how icotrokinra's approval in this group and its once-daily dosing affect the treatment conversation.

Andrew Mastro, MS, PA-C, asks Alexa Hetzel, MS, PA-C, to place icotrokinra alongside the oral agents clinicians have relied on to date, apremilast and deucravacitinib.

Trace how oral plaque psoriasis therapy has evolved over time, from PDE4 and TYK2 inhibition to once-daily oral peptides.

Explore why therapeutic inertia keeps plaque psoriasis patients cycling through topicals instead of escalating to systemic therapy.

Experts in dermatology share practice pearls to advanced practice providers and community dermatologists for the management of plaque psoriasis.

Jayme M. Heim, MSN, FNP-BC, discusses unmet needs in the treatment landscape of plaque psoriasis.

Douglas DiRuggiero, DMSc, PA-C, reviews how deucravacitinib impacts the quality of life for patients with plaque psoriasis.

Darren West, MPAS, PA-C, shares how often follow-up is required with deucravacitinib therapy in plaque psoriasis.

Andrea Nguyen, PA-C, MS, provides an overview of the safety considerations of deucravacitinib for the treatment of plaque psoriasis.

Experts in dermatology discuss what patients to consider treating with deucravacitinib, as well as comment on the comparative safety and efficacy of other therapies.

Experts in dermatology discuss the importance of deucravacitinib being an expansion of oral treatment modalities for plaque psoriasis, as well as the long-term data.

Jayme M. Heim, MSN, FNP-BC, reviews deucravacitinib as an oral treatment for moderate to severe plaque psoriasis, describing its unique mechanism of action.

Douglas DiRuggiero, DMSc, PA-C, discusses factors that contribute to switching a patient with plaque psoriasis from a topical to a systemic agent.

Darren West, MPAS, PA-C, reviews treatment failure as criteria for advanced practice providers to utilize a step-up treatment approach.

Andrea Nguyen, MS, PA-C, reviews commonly used therapies for the initial treatment of plaque psoriasis.

Jayme M. Heim, MSN, FNP-BC, discusses the various challenges care providers face when selecting treatment for patients with plaque psoriasis.

Douglas DiRuggiero, DMSc, PA-C, shares his approach to building trust in the patient-provider relationship when counseling patients about treatment of plaque psoriasis.

Darren West, MPAS, PA-C, and Douglas DiRuggiero, DMSc, PA-C, talk about how the treatment of plaque psoriasis has changed as understanding of the disease grows.

Experts in dermatology discuss how clinician understanding of plaque psoriasis has evolved over time.

Jayme M. Heim, MSN, FNP-BC, comments on the need for multidisciplinary care providers in light of comorbidities in plaque psoriasis.

Douglas DiRuggiero, DMSc, PA-C, reviews the role of nurse practitioners, physician assistants, and pharmacists in managing plaque psoriasis.

Alexa Hetzel, MA, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, and Matthew Brunner, PA, share practice pearls and clinical management tips for the care of pediatric patients with atopic dermatitis.

Experts in dermatology hypothesize about the next round of treatment disruptions and their hopes for the future of atopic dermatitis management.

Alexa Hetzel, MA, PA-C, and Lakshi Aldredge, MSN, ANP-BC, DCNP, provide insight into emerging therapies and ongoing investigations in the management of pediatric atopic dermatitis.